Bronchogenic Carcinoma in Patients Seropositive for Human Immunodeficiency Virus

Tenholder, Michael F.; Jackson, Harold D.

doi:10.1378/chest.104.4.1049

Cited by 36 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have failed to demonstrate a direct correlation between absolute CD4 count and lung cancer risk, which may be attributed in part to variability in the CD4 count. 5,10,11,15,17,[24][25][26][27][28] In the current study, we demonstrated that smoking was associated with a higher CD4 count, as reported in other studies, 29 supporting smoking as 1 of many factors that affect the absolute CD4 count.…”

Section: Discussionsupporting

confidence: 86%

Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy

Pakkala

Rimland

Owonikoko

et al. 2011

Cancer

View full text Add to dashboard Cite

Background Lung cancer is the leading cause of death among non-acquired immunodeficiency syndrome (AIDS) defining malignancies. Since highly active anti-retroviral therapy (HAART) has improved survival for human immunodeficiency virus (HIV) patients, we evaluated lung cancer outcomes in the HAART era. Methods HIV-positive patients diagnosed with lung cancer in our institution during the HAART era (1995-2008) were analyzed. Patient charts were reviewed for clinical and laboratory data. CD4 count at diagnosis was treated as a continuous variable and subcategorized into distinct variables with 3 cut-off points (50, 200, & 500 μl). Pearson’s correlation coefficients were estimated for each covariate studied. Survival was determined by the Kaplan-Meier method. Results Out of 80 patients, 73 had non-small cell lung cancer. Baseline characteristics were: median age-52 yrs; male-80%; African American-84%; injection drug use-25%; smokers-100%; and prior exposure to antiretroviral agents-55%. Mean CD4 count and viral load were 304 μL and 82,420 copies/ml, respectively at cancer diagnosis. The latency between diagnosis of HIV and lung cancer was significantly shorter in women (4.1 yrs vs. 7.7 yrs, P=0.02) and 71% of the patients received anti-cancer therapy. The 1- and 3-year survival rates were 31% and 4% overall. Grade 3/4 toxicities occurred in 60% with chemo-radiation vs. 36% with chemotherapy. Cancer-related survival was better for patients with CD4 count >200 (P=0.0298) and >500 (P=0.0076). Conclusions The latency from diagnosis of HIV to lung cancer was significantly shorter for women. Although outcomes for lung cancer patients with HIV remain poor, high CD4 count is associated with an improved lung cancer-related survival.

show abstract

Section: Discussionsupporting

confidence: 86%

Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy

Pakkala

Rimland

Owonikoko

et al. 2011

Cancer

View full text Add to dashboard Cite

show abstract

“…Several large databases have suggested that certain solid tumors can be overrepresented in this patient population (7,16,17,68,69). Bronchogenic carcinoma as well as melanoma, colon cancer, and breast cancer appear to occur with increased frequency even when other risk factors are considered.…”

Section: Neoplastic Diseasementioning

confidence: 96%

Management of Patients with HIV in the Intensive Care Unit

Masur¹

2006

Proceedings of the American Thoracic Society

View full text Add to dashboard Cite

“…More recent studies have indicated an increase in incidence of primary lung cancer in patients with HIV infection [22,29]. Although there was no case of adenocarcinoma in the PIP study, it is the predominant cell type of bronchogenic carcinoma in patients with HIV infection [22,26,30]. The Pulmonary Complications of HIV Infection Study Group has shown upper respiratory infection and bronchitis to be common in patients with HIV infection [3].…”

Section: Discussionmentioning

confidence: 99%

Mycobacterial and nonbacterial pulmonary complications in hospitalized patients with human immunodeficiency virus infection: A prospective, cohort study

Afessa

2001

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

Bronchogenic Carcinoma in Patients Seropositive for Human Immunodeficiency Virus

Cited by 36 publications

References 11 publications

Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy

Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy

Management of Patients with HIV in the Intensive Care Unit

Mycobacterial and nonbacterial pulmonary complications in hospitalized patients with human immunodeficiency virus infection: A prospective, cohort study

Contact Info

Product

Resources

About